Tata Trusts to provide cancer care across Telangana

The agreement was signed by the state government representatives and the chairman of Tata Trusts Ratan Tata on Thursday, Tata Trusts said in a statement.

author-image
Assem Sharma
Updated On
New Update
Tata Trusts to provide cancer care across Telangana

Tata Trusts to provide cancer care across Telangana(Source - file pic)

Tata Trusts, the largest public charity in the country, has inked an agreement with Telangana to deliver high quality affordable cancer care through a three-tier model, and develop academic and research capabilities in the state.

The agreement was signed by the state government representatives and the chairman of Tata Trusts Ratan Tata on Thursday, Tata Trusts said in a statement.

As part of the three-tier model, two apex super- speciality hospitals in Hyderabad - the MNJ Institute of Technology and the Nizam Institute of Medical Sciences - will be upgraded to handle complex cases on a referral basis.

Also, medical colleges in Adilabad, Nizamabad, Mahbubnagar and Warangal will be strengthened to offer diagnosis and treatment of cancer cases.

That apart district hospitals in Karimnagar, Khammam and Nalgonda will also be developed to offer diagnostic and standardised day care chemotherapy.

The network will ensure that no patient will have to travel more than a few hours for accessing the full suite of cancer treatment services, the statement said.

Speaking on the occasion Tata said, "the Tats Trusts is privileged to partner with Telangana in upgrading cancer care capabilities in the public health network. Patients will no longer need to travel all the way to Hyderabad except for rare and complex conditions."

The initiative in Telangana is the latest of Tata Trusts' effort to partner with states and other entities to decentralise cancer care. Similar initiatives are in different stages of implementation in Assam, Maharashtra and UP. Glenmark to sell Danish co's hair treatment tablet

Hyderabad: Glenmark Pharmaceuticals has launched tablets to normalise hair growth cycle named Nourkrin Woman for the domestic market.

The drug will be marketed exclusively by Glenmark under a licensing agreement with Denmark-headquartered firm Pharma Medico, the drug maker said on Thursday.

Nourkrin Woman contains Marilex, a proprietary scientific formula, rich in specific proteoglycans essential for hair follicle development, which helps in normalizing, supporting and maintaining the hair growth cycle, it added.

According to Rajesh Kapur of Glenmark, 60 per cent women experience hair loss at some stage in their lives and there are over 90 million women reported to have hair loss in the country.

Tata Trusts ratan tata